(Q42679416)

4 November 2017

title

Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms (English)

1 reference

4 November 2017

5

1 reference

4 November 2017

Chen-Hsun Ho

1

1 reference

4 November 2017

Ting-Chen Chang

2

1 reference

4 November 2017

Ho-Hsiung Lin

3

1 reference

4 November 2017

Shih-Ping Liu

4

1 reference

4 November 2017

Hong-Jeng Yu

6

1 reference

4 November 2017

publication date

1 October 2010

1 reference

Journal of the Formosan Medical Association

4 November 2017

published in

1 reference

4 November 2017

volume

109

1 reference

4 November 2017

issue

10

1 reference

4 November 2017

page(s)

702-708

1 reference

The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960114-3

7 January 2021

Prevalence and correlation of urinary incontinence and overactive bladder in Taiwanese women

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960114-3

7 January 2021

Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960114-3

7 January 2021

Prevalence and burden of overactive bladder in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960114-3

7 January 2021

Antimuscarinics for treatment of overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960114-3

7 January 2021

Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960114-3

7 January 2021

Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960114-3

7 January 2021

Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960114-3

7 January 2021

Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960114-3

7 January 2021

A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960114-3

7 January 2021

Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960114-3

7 January 2021

The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960114-3

7 January 2021

Muscarinic receptor antagonists for overactive bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960114-3

7 January 2021

Muscarinic receptors of the urinary bladder: detrusor, urothelial and prejunctional.

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960114-3

7 January 2021

Bladder activation: afferent mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960114-3

7 January 2021

Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions?

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960114-3

7 January 2021

The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960114-3

7 January 2021

Using anticholinergics to treat overactive bladder: the issue of treatment tolerability

1 reference

https://api.crossref.org/works/10.1016%2FS0929-6646%2810%2960114-3

7 January 2021

10.1016/S0929-6646(10)60114-3

Identifiers

DOI

1 reference

4 November 2017

1 reference